Fosinopril
- Generic Name
- Fosinopril
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H46NO7P
- CAS Number
- 98048-97-6
- Unique Ingredient Identifier
- R43D2573WO
- Background
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood p...
- Indication
For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
- Associated Conditions
- Heart Failure, Hypertension
- Associated Therapies
- -
Prevention of Renal and Vascular Endstage Disease Intervention Trial
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 864
- Registration Number
- NCT03073018
Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 508
- Registration Number
- NCT02646397
- Locations
- 🇨🇳
Department of Nephrology, Shanghai Changzheng Hospital, Shanghai, Shanghai, China
The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- China-Japan Friendship Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT01342614
Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 80
- Registration Number
- NCT01014338
- Locations
- 🇬🇧
Royal Brompton Hospital, London, United Kingdom
Eplerenone, ACE Inhibition and Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00315016
- Locations
- 🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Noord Brabant, Netherlands
🇳🇱University Medical Center Nijmegen St Radboud, Nijmegen, Netherlands
ACE Inhibition and Novel Cardiovascular Risk Factors
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.